Streamex Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Streamex de 114.5% y 106.4% respectivamente, mientras que el BPA crecerá en un 117.5% al año.
Información clave
114.5%
Tasa de crecimiento de los beneficios
117.50%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 16.1% |
| Tasa de crecimiento de los ingresos | 106.4% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 21 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Nueva narrativa • Apr 09
Tokenized Commodity Yield Platform Will Benefit From Growing Real World Asset Adoption
Catalysts About Streamex Streamex operates a capital light platform focused on tokenized commodity assets such as yield bearing gold and planned silver, copper and energy linked products. What are the underlying business or industry changes driving this perspective?Artículo de análisis • Dec 12
Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now
Key Insights BioSig Technologies will host its Annual General Meeting on 18th of December Salary of US$865.7k is part...Artículo de análisis • Dec 14
Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why
Shareholders of BioSig Technologies, Inc. ( NASDAQ:BSGM ) will have been dismayed by the negative share price return...Seeking Alpha • Oct 07
BioSig in acquisition pact with San Antonio Hospital for cardiac signal system
Medical device maker BioSig Technologies, Inc. (NASDAQ:BSGM) announced that the company entered into a purchase agreement with San Antonio Methodist Hospital allowing the latter to acquire its PURE EP System, a cardiac signal processing system. According to a regulatory filing on Thursday, the company executed the deal on Sep. 30 In July, BSGM announced a leasing deal under which the Overland Park Regional Medical Center agreed to acquire the PURE EP System, marking the first transaction since its nationwide launch. "Establishing a contract with a leading national hospital network is a milestone achievement for BioSig Technologies," BSGM Chief Commercial Officer Gray Fleming said at the time. "A leasing option provides a cost-effective and efficient pathway for hospitals to acquire our technology," he added.Seeking Alpha • Sep 08
BioSig: No Changes To Hold Thesis Following Q2 Earnings
Summary BioSig continues to be presented with systematic challenges that place it behind other selective opportunities in med-tech. Cash flows are priced out well into the future and the predictability of these is low in the current landscape. We note updates around PURE EP continue to receive a muted market reaction upon release. Here we reiterate the hold rating on BSGM. From the Portfolio Manager's Desk Unprofitable med-tech continues to face systematic headwinds as the market looks to match mispricings in fundamentals to future expectations. However, risk-assets have caught a bid since June and that's meant high-beta names have clawed back some of the losses incurred in FY22. We've made no changes to our thesis on BioSig Technologies, Inc. (BSGM) from my previous analysis in June. We also covered BioSig in late 2020. We encourage investors to factor a data driven approach in this name until there is some fundamental value to be derived. Investment Summary We reiterate a hold rating on BSGM following Q2 earnings as systematic headwinds remain for this name. We note the stock has caught a bid since the June bounce however we argue this is likely beta related rather than some unidentified or uncorrelated premia BSGM is presenting relative to peers. With cash flows still priced well out into the future, BSGM is one to be watched from the sidelines from now for a defensively positioned equity portfolio. Rate hold on a $1 valuation. Risks to investment thesis Investing in small-cap equities comes with inherent risks that must be factored in before investment decision. Moreover, investing in commercial stage medical device companies carries its own set of downside risks. Being a neutral stance, there is both upside and downside risks to our investment thesis. In addition, small-cap equities can become disconnected from fundamentals upon news releases or wider market actions and display wide volatility in price swings. These risks pose a threat to this investment thesis and must be considered heavily into one's investment reasoning when reading this analysis. Recent upside likely beta related Quantitative analysis of recent stock returns points to the fact the upside is likely due to equity market and sector-beta rather than company-specific risk premia. As seen in Exhibit 1, since the leg upward from the July bounce, BSGM's equity beta to the S&P/500 also shifted well above 1 and has remained buoyant since. This tells us that investors are buyers of BGSM in seeking strategic equity/health care exposure, versus tactical positioning from active managers/investors. Exhibit 1. Up-shift in covariance structure accompanying the latest leg in the BGSM share price suggesting recent upside is likely equity beta versus idiosyncratic risk/return Data: Updata Further evidence of the above is seen in Exhibit 2. As noted, health care as an investment universe has caught a bid since the June bounce along with positioning in risk-assets. However, we note that BSGM's correlation to the medical devices and health care index equipment has also shifted up since May. As a result, we question if the recent upside is a function of certain investors having identified in BGSM that the market consensus has overlooked, or, just a function of sector-beta, as mentioned. We are leaning towards the latter. Exhibit 2. Correlations to med-tech and health care benchmarks also lifting since early May raising questions on where we can attribute the source of recent equity returns from in BGSM Both charts [above and below] demonstrate a tight dispersion between equity market and sector beta and the BGSM share price since it began to tick up in August Data: Updata Pure EP updates still priced in As has been the case with BSGM, the growth engine centres around PURE EP and updates around the same. However, as has also been the case this year, investors have priced in additional updates quickly and with little amplitude. Most recently on 24 August it reported that it had installed a second evaluation system at the Cleveland Clinic, expanding physician access to the company's 'signal' technology. However, the market's reaction was mute, as has been the case previously. In particular, we note the market's muted reaction to the news BSGM will reduce product evaluations down to 60 days from 180-360 days. However, there's still no revenue booked for the segment, in preparation for the commercial rollout. We mentioned in June that, "BSGM likely has revenue tailwinds set to be realised in H2 FY22, with a ramp up in sales predicted into the coming years pending a successful launch." This likely has been overshot and we now look to Q4 to see some form of how the company intends to proceed with its sales strategy looking ahead. The question then turns to what exactly are we paying for today in BSGM. Shares are priced at more than 7.1x book value, on shareholder equity of $6.8mm and book value per share of $0.15. It's also priced at 6.6x enterprise value ("EV") to book value. At this multiple we'd be paying an implied price of $1.00, suggesting the market consensus has the stock fairly discounted at its current market capitalization. Moreover, and looking at the balance sheet, we're buying into a capital structure that is weighted towards equity holders, with $596mm in tangible assets and $317mm in patents that it amortizes on a straight-line basis over 20 years. However, we're not buying into any substantiated return on any of this capital investment, and we are set to pay what looks like fair value for cash flows priced well out into the future. This degree of uncertainty keeps us trigger shy on the name. Technical factors With a lack of fundamental data, we checked the market's psychology around the stock and noted there remains a downside bias in price action. As seen in Exhibit 3, there are downside targets clustered towards the $0.85-$0.92 region. The stock has set a series of lower highs and is again testing the inner resistance line shown below. From this chart, price action appears to be bearish, and unsupportive of near-term upside.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 282 | 195 | N/A | N/A | 1 |
| 12/31/2027 | 97 | 59 | N/A | N/A | 1 |
| 12/31/2026 | 8 | -51 | N/A | N/A | 1 |
| 3/31/2026 | N/A | -507 | -20 | -20 | N/A |
| 12/31/2025 | N/A | -463 | -10 | -10 | N/A |
| 9/30/2025 | 0 | -40 | -8 | -8 | N/A |
| 6/30/2025 | 0 | -26 | -4 | -4 | N/A |
| 3/31/2025 | 0 | -10 | -5 | -5 | N/A |
| 12/31/2024 | 0 | -11 | -5 | -5 | N/A |
| 9/30/2024 | 0 | -15 | -7 | -7 | N/A |
| 6/30/2024 | 0 | -18 | -10 | -10 | N/A |
| 3/31/2024 | 0 | -25 | -13 | -13 | N/A |
| 12/31/2023 | 0 | -29 | -17 | -17 | N/A |
| 9/30/2023 | 0 | -30 | -19 | -18 | N/A |
| 6/30/2023 | 0 | -32 | -20 | -20 | N/A |
| 3/31/2023 | 0 | -27 | -22 | -21 | N/A |
| 12/31/2022 | 0 | -27 | -22 | -22 | N/A |
| 9/30/2022 | 0 | -29 | -24 | -23 | N/A |
| 6/30/2022 | 0 | -30 | -26 | -25 | N/A |
| 3/31/2022 | 0 | -32 | -26 | -25 | N/A |
| 12/31/2021 | 0 | -32 | -27 | -26 | N/A |
| 9/30/2021 | 0 | -34 | -27 | -27 | N/A |
| 6/30/2021 | 0 | -38 | -27 | -26 | N/A |
| 3/31/2021 | 0 | -49 | -28 | -28 | N/A |
| 12/31/2020 | N/A | -52 | -27 | -27 | N/A |
| 9/30/2020 | N/A | -57 | -25 | -24 | N/A |
| 6/30/2020 | N/A | -51 | -22 | -22 | N/A |
| 3/31/2020 | N/A | -40 | -18 | -18 | N/A |
| 12/31/2019 | N/A | -34 | N/A | -15 | N/A |
| 9/30/2019 | N/A | -25 | N/A | -15 | N/A |
| 6/30/2019 | N/A | -23 | N/A | -13 | N/A |
| 3/31/2019 | N/A | -21 | N/A | -11 | N/A |
| 12/31/2018 | N/A | -18 | N/A | -10 | N/A |
| 9/30/2018 | N/A | -17 | N/A | -10 | N/A |
| 6/30/2018 | N/A | -15 | N/A | -9 | N/A |
| 3/31/2018 | N/A | -12 | N/A | -8 | N/A |
| 12/31/2017 | N/A | -13 | N/A | -7 | N/A |
| 9/30/2017 | N/A | -10 | N/A | -6 | N/A |
| 6/30/2017 | N/A | -9 | N/A | -6 | N/A |
| 3/31/2017 | N/A | -12 | N/A | -6 | N/A |
| 12/31/2016 | N/A | -12 | N/A | -5 | N/A |
| 9/30/2016 | N/A | -12 | N/A | -5 | N/A |
| 6/30/2016 | N/A | -11 | N/A | -5 | N/A |
| 3/31/2016 | N/A | -9 | N/A | -4 | N/A |
| 12/31/2015 | N/A | -10 | N/A | -5 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -4 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que STEX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que STEX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que STEX sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (106.4% al año) de STEX crezcan más rápidamente que los del mercado US (11.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (106.4% al año) de STEX crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de STEX se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 11:22 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Streamex Corp. está cubierta por 2 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| John Todaro | Needham & Company |
| Scott Henry | Roth Capital Partners |